VGXI News and Resources

VGXI, Inc., a contract developer and manufacturer of nucleic acid biopharmaceuticals has announced a strategic partnership with Cryoport, Inc., a global provider in life sciences supply chain solutions. The collaboration aims to support biopharmaceutical companies in developing advanced therapies, including

VGXI, Inc., a contract developer and manufacturer (CDMO) specialising in nucleic acid biopharmaceuticals, has been selected to join the Rapid Response Partnership Vehicle (RRPV). This partnership supports the Biomedical Advanced Research and Development Authority (BARDA) in accelerating the development of

VGXI a contract developer and manufacturer specialising in plasmid DNA, has announced a strategic partnership with Sutro Biopharma, Inc., to support the clinical production of a novel cancer treatment, luveltamab tazevibulin, also known as luvelta. This antibody-drug conjugate is designed